The Power of Personalized Medicine

Cancer Genetics, Inc. (CGI) is a leader in drug discovery and preclinical oncology and immuno-oncology services. Through the acquisition of vivoPharm, the Company offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings.

Personalized medicine aims to provide each individual patient with the therapy they are most likely to respond to. By assessing each patient and their tumor’s unique genetic information, we can help doctors provide the most accurate diagnosis, prognosis, and treatment selection available.

Today only 25% of initial cancer treatments are successful. This is in part due to the traditional approach to treatment, which has tended to give each patient with the same disease, the same treatment. Because personalized medicine takes into account each tumor’s and each individual’s unique genetic makeup, we support the development of individualized treatment therapies and help improve success rates in cancer treatment.

Our history of groundbreaking work in the area of genetics-based testing has helped thousands of patients because it makes personalized medicine possible. Every person is different, and every cancer is different. Genetic-based testing identifies a person’s cancer at a molecular level.

Links & Resources

General Cancer Information

Oncologist Organizations

Resources for Urogenital Cancers

Resources for Blood Cancers

Resources for Other Cancer Types